- Home
- DOUG vs SLS Comparison
DOUG vs SLS Comparison
Compare DOUG & SLS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- DOUG
- SLS
- Stock Information
- Founded
- DOUG 1911
- SLS 2012
- Country
- DOUG United States
- SLS United States
- Employees
- DOUG N/A
- SLS N/A
- Industry
- DOUG Building operators
- SLS Biotechnology: Pharmaceutical Preparations
- Sector
- DOUG Real Estate
- SLS Health Care
- Exchange
- DOUG Nasdaq
- SLS Nasdaq
- Market Cap
- DOUG 161.5M
- SLS 169.6M
- IPO Year
- DOUG N/A
- SLS N/A
- Fundamental
- Price
- DOUG $2.61
- SLS $1.54
- Analyst Decision
- DOUG
- SLS
- Analyst Count
- DOUG 0
- SLS 0
- Target Price
- DOUG N/A
- SLS N/A
- AVG Volume (30 Days)
- DOUG 1.3M
- SLS 2.5M
- Earning Date
- DOUG 08-06-2025
- SLS 08-12-2025
- Dividend Yield
- DOUG N/A
- SLS N/A
- EPS Growth
- DOUG N/A
- SLS N/A
- EPS
- DOUG N/A
- SLS N/A
- Revenue
- DOUG $1,048,791,000.00
- SLS N/A
- Revenue This Year
- DOUG $17.61
- SLS N/A
- Revenue Next Year
- DOUG N/A
- SLS N/A
- P/E Ratio
- DOUG N/A
- SLS N/A
- Revenue Growth
- DOUG 11.36
- SLS N/A
- 52 Week Low
- DOUG $1.03
- SLS $0.77
- 52 Week High
- DOUG $3.20
- SLS $2.12
- Technical
- Relative Strength Index (RSI)
- DOUG 54.35
- SLS 45.96
- Support Level
- DOUG $2.60
- SLS $1.47
- Resistance Level
- DOUG $3.00
- SLS $1.73
- Average True Range (ATR)
- DOUG 0.16
- SLS 0.11
- MACD
- DOUG -0.04
- SLS -0.02
- Stochastic Oscillator
- DOUG 20.49
- SLS 19.44
About DOUG Douglas Elliman Inc.
Douglas Elliman Inc is a real estate company. It offers sales, rentals, and new development to mortgages and title insurance, among other services related to real estate. Business is engaged in two operating segments Real Estate Brokerage and Corporate and other. The firm generates income from Commission and other brokerage revenue from existing home sales, Commission and other brokerage income from development marketing, Property management revenue and Title fees. It derives revenue from Real Estate Brokerage segment.
About SLS SELLAS Life Sciences Group Inc.
SELLAS Life Sciences Group Inc is a late-stage clinical biopharmaceutical company focused on the development of novel therapeutics for a broad range of cancer indications. The company's product candidates currently include galinpepimut-S, or GPS, a peptide immunotherapy directed against the Wilms tumor 1, or WT1, antigen, and GFH009, a selective small molecule cyclin-dependent kinase 9, or CDK9, inhibitor.